Regenxbio Inc.

Ticker RGNX

Exchange NASDAQ More
Industry Biotechnology More
Sector Healthcare More

51-200 Employees
Based in Rockville, Maryland

REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. REGENXBIO’s NAV® Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform, consists of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10. REGENXBIO and its third-party NAV Technology Licensees…More

Visit website

REPORT RATINGS

4.8 / 5.0 (192)

Regenxbio Inc. reports have an aggregate usefulness score of 4.8 based on 192 reviews.

Regenxbio Inc.

Most Recent Annual Report

MOST RECENT 2023 Annual Report and Form 10K

View PDF View Form 10K (HTML)

Regenxbio Inc. does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Please fill out the form below and click "Place Order" to complete your order.